Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TREACE MEDICAL CONCEPTS, INC. (TMCI)

Treace Medical lifts 2026 revenue guidance low end to $202 million; CCO departs

Positive Impact 4 of 5 guidance Written later

Treace Medical preliminarily reported first-quarter 2026 revenue of $47.0 million to $47.2 million and cash of about $51.9 million, and raised the low end of its full-year 2026 revenue guidance to $202 million to $212 million. The company also said Chief Commercial Officer Gaetano M. Guglielmino departed effective April 8, 2026, and will not be replaced, with his duties moved to existing staff and the head of sales reporting to the CEO.

Key points

  • Preliminary Q1 2026 revenue: $47.0 million to $47.2 million (unaudited; subject to financial closing procedures)
  • Cash, equivalents and marketable securities about $51.9 million at March 31, 2026, up about $3.5 million from $48.4 million at December 31, 2025
  • 2026 revenue guidance updated to $202 million to $212 million, from $200 million to $212 million previously
  • Chief Commercial Officer Gaetano M. Guglielmino departed April 8, 2026; consulting agreement runs through January 31, 2027 at a monthly fee of $36,666.67

The filing

CompanyTREACE MEDICAL CONCEPTS, INC. (TMCI)
Form8-K, current report
Filed with the SECApr 9, 2026, 7:00 AM ET
Accession number0001630627-26-000010

Items reported: 2.02 Results of Operations5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.